Certified by Founder Lodge
Ascend Gene & Cell Therapies
United Kingdom - London
START UP
1 Disclosed Funding Rounds $132,500,000
0 Participating Investments
-
Founded date
2021
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
At Ascend we aim high.
Ascend was founded to address the need for quality manufacturing capacity for any gene and cell therapy developer. We offer starting material, process and formulatio
| Date | Round | Raised | Participating Investors |
|---|---|---|---|
| May, 10 ,2023 | Series A | $132,500,000 |
Digitalis Ventures
Abingworth
Cathay Health
Monograph Capital
DCVC Bio
Deerfield Management
Petrichor Healthcare Capital Management
4BIO Capital
Carmot Therapeutics, Inc.
Ozette Technologies
NAPIGEN, INC.
TrueBinding
Loopworm
Helex | $3,500,000 | (Nov 4, 2025)
xMEMS | $21,000,000 | (Nov 4, 2025)
catalyx space | $5,400,000 | (Nov 4, 2025)
Cephia AI | $4,000,000 | (Nov 4, 2025)
Ornn | $5,700,000 | (Nov 4, 2025)
